Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Movement Movement +8.01%
#3 COTI COTI +7.56%
#4 DMT-NAT DMT-NAT +7.27%
#5 Victoria VR Victoria VR +7.18%
#6 GRVT Token GRVT Token +4.67%
#7 Cryptopia Cryptopia +3.74%
#8 Kinetiq Kinetiq +3.53%
#9 Lisk Lisk +3.28%
#10 Jito Jito +3.02%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
設定
言語
日本
通貨
USD
テーマ
Xeno Transplants Corporation Xeno Transplants Corporation

Xeno Transplants Corporation

XENO
株式のランク #42146
Xeno Transplants Corporation functions as a biotechnology firm dedicated to... Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants. This is achieved by pioneering techniques that enable the transfer of biological components—such as cells, tissues, and organs—from non-human species, including pigs, into human recipients. Established in 2004, Xeno Transplants Corporation maintains its headquarters in Brookline, Massachusetts.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$4.04K
変化（1日）
0.00%
変化（1年）
0.00%
国
CA
取引 Xeno Transplants Corporation (XENO)

カテゴリー

Healthcare
Xeno Transplants Corporation（XENO）の収益
Aug 2026 時点の収益 TTM: 0
Xeno Transplants Corporation の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Xeno Transplants Corporation の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR